Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

S. Sahasranaman · SciRah

Researcher profile · Semantic Scholar

S. Sahasranaman

Share profile

S. Sahasranaman — researcher profile on SciRah

h-index: 19
Works: 56
Citations: 1,551

Most-cited papers

Clinical pharmacology and pharmacogenetics of thiopurines
S. Sahasranaman, D. Howard, Sandip K. Roy
2008European Journal of Clinical Pharmacology404 citations
Semantic Scholar
A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia
T. Kipps, H. Eradat, S. Grosicki, J. Catalano +8 more
2015Leukemia and Lymphoma186 citations Open access
Semantic Scholar
Immune Checkpoint inhibitors: An introduction to the next‐generation cancer immunotherapy
Lucy Lee, M. Gupta, S. Sahasranaman
2016Journal of clinical pharmacology126 citations Open access
Semantic Scholar
The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys.
L. Grégoire, Nicolas Morin, B. Ouattara, F. Gasparini +6 more
2011Parkinsonism & Related Disorders112 citations
Semantic Scholar
Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development
Anand Rotte, S. Sahasranaman, N. Budha
2021Biomedicines67 citations Open access
Semantic Scholar
Phase I Study of GDC-0425, a Checkpoint Kinase 1 Inhibitor, in Combination with Gemcitabine in Patients with Refractory Solid Tumors
J. Infante, A. Hollebecque, S. Postel-Vinay, T. Bauer +14 more
2016Clinical Cancer Research63 citations Open access
Semantic Scholar
Plasma concentrations of inhaled corticosteroids in relation to airflow obstruction in asthma.
K. Mortimer, T. Harrison, Yu-Fei Tang, Kai Wu +4 more
2006British Journal of Clinical Pharmacology56 citations Open access
Semantic Scholar
Model-Based Covariate Pharmacokinetic Analysis and Lack of Cortisol Suppression by the New Inhaled Corticosteroid Ciclesonide Using a Novel Cortisol Release Model
S. Rohatagi, S. Krishnaswami, M. Pfister, S. Sahasranaman
2005American Journal of Therapeutics39 citations
Semantic Scholar
Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects
S. Mu, Zhiyu Tang, W. Novotny, M. Tawashi +3 more
2019Cancer Chemotherapy and Pharmacology37 citations Open access
Semantic Scholar
Effect of OATP1B1/1B3 Inhibitor GDC‐0810 on the Pharmacokinetics of Pravastatin and Coproporphyrin I/III in Healthy Female Subjects
Li-Chuan Liu, S. Cheeti, K. Yoshida, Edna F. Choo +7 more
2018Journal of clinical pharmacology37 citations
Semantic Scholar
Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma
Y. Ou, Zhiyu Tang, W. Novotny, A. Cohen +4 more
2021Leukemia and Lymphoma33 citations Open access
Semantic Scholar
GDC-0810 Pharmacokinetics and Transporter-Mediated Drug Interaction Evaluation with an Endogenous Biomarker in the First-in-Human, Dose Escalation Study
K. Cheung, K. Yoshida, S. Cheeti, Buyun Chen +4 more
2019Drug Metabolism And Disposition30 citations Open access
Semantic Scholar
Population Pharmacokinetic Analysis of the BTK Inhibitor Zanubrutinib in Healthy Volunteers and Patients With B‐Cell Malignancies
Y. Ou, Lucy Liu, B. Tariq, Kun Wang +4 more
2020Clinical and Translational Science28 citations Open access
Semantic Scholar
Comprehensive PBPK model to predict drug interaction potential of Zanubrutinib as a victim or perpetrator
Kun Wang, Xue-Ting Yao, Miao Zhang, Dong-Yang Liu +3 more
2021CPT: Pharmacometrics & Systems Pharmacology25 citations Open access
Semantic Scholar
METABOLISM OF MOMETASONE FUROATE AND BIOLOGICAL ACTIVITY OF THE METABOLITES
S. Sahasranaman, M. Issar, G. Hochhaus
2006Drug Metabolism And Disposition24 citations
Semantic Scholar
Evaluation of drug interaction potential of zanubrutinib with cocktail probes representative of CYP3A4, CYP2C9, CYP2C19, P‐gp and BCRP
Y. Ou, Zhiyu Tang, W. Novotny, M. Tawashi +3 more
2020British Journal of Clinical Pharmacology22 citations Open access
Semantic Scholar
Strategies to address drug interaction potential for antibody-drug conjugates in clinical development.
D. Lu, S. Sahasranaman, Yi Zhang, S. Girish
2013Bioanalysis22 citations
Semantic Scholar
A sensitive liquid chromatography-tandem mass spectrometry method for the quantification of mometasone furoate in human plasma.
S. Sahasranaman, Yu-Fei Tang, D. Biniasz, G. Hochhaus
2005Journal of chromatography. B, Analytical technologies in the biomedical and life sciences20 citations
Semantic Scholar
A phase 1, open-label, single-dose study of the pharmacokinetics of zanubrutinib in subjects with varying degrees of hepatic impairment
Y. Ou, R. Preston, T. Marbury, Zhiyu Tang +4 more
2020Leukemia and Lymphoma19 citations
Semantic Scholar
Evaluation of HDL-modulating interventions for cardiovascular risk reduction using a systems pharmacology approach
K. Gadkar, James Lu, S. Sahasranaman, John Davis +2 more
2016Journal of Lipid Research19 citations Open access
Semantic Scholar
Model‐based population pharmacokinetic analysis of tislelizumab in patients with advanced tumors
N. Budha, Chi-Yuan Wu, Zhiyu Tang, Tian Yu +7 more
2022CPT: Pharmacometrics & Systems Pharmacology17 citations Open access
Semantic Scholar
No QTc Prolongation With Zanubrutinib: Results of Concentration‐QTc Analysis From a Thorough QT Study in Healthy Subjects
S. Mu, B. Darpo, Zhiyu Tang, W. Novotny +6 more
2020Clinical and Translational Science13 citations Open access
Semantic Scholar
Assessment of OATP transporter‐mediated drug–drug interaction using physiologically‐based pharmacokinetic (PBPK) modeling – a case example
Yuan Chen, Rui Zhu, Fang Ma, J. Mao +4 more
2018Biopharmaceutics & drug disposition12 citations
Semantic Scholar
Intranasal glucocorticoid delivery: competition between local and systemic effects
G. Hochhaus, S. Sahasranaman, H. Derendorf, H. Möllmann
200212 citations
Semantic Scholar
Characterization of degradation products of mometasone furoate.
S. Sahasranaman, M. Issar, G. Tóth, G. Horváth +1 more
2004Pharmazie11 citations
Semantic Scholar
In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor
Heather Zhang, Y. Ou, Dan Su, Fan Wang +3 more
2021Pharmacology Research & Perspectives10 citations Open access
Semantic Scholar
Complete chemical control of stoichiometry of materials related to high Tc ceramics RBa2Cu3O7−x (R=rare earth)
S. Antony, K. S. Nagaraja, S. Sahasranaman, O. M. Sreedharan
19999 citations
Semantic Scholar
Absorption, Metabolism, and Excretion of Taselisib (GDC-0032), a Potent β-Sparing PI3K Inhibitor in Rats, Dogs, and Humans
Shu-Guang Ma, Sung-Ji Cho, S. Sahasranaman, Weiping Zhao +7 more
2023Drug Metabolism And Disposition8 citations
Semantic Scholar
Clinical dose rationale of tislelizumab in patients with solid or hematological advanced tumors
Tian Yu, Xiangyu Liu, Chi-Yuan Wu, Zhiyu Tang +8 more
2024Clinical and Translational Science7 citations Open access
Semantic Scholar
Human Mass Balance and Metabolite Profiling of [14C]‐Pamiparib, a Poly (ADP‐Ribose) Polymerase Inhibitor, in Patients With Advanced Cancer
S. Mu, D. Palmer, Richard J. Fitzgerald, C. Andreu-Vieyra +4 more
2021Clinical pharmacology in drug development7 citations Open access
Semantic Scholar
Preliminary Results of a Phase II Open-Label, Randomized Study of the BH3 Mimetic Protein Navitoclax (ABT-263) with or without Rituximab for Treatment of Previously Untreated B-Cell Chronic Lymphocytic Leukemia
H. Eradat, S. Grosicki, John Catalono, W. Cosolo +8 more
20127 citations
Semantic Scholar
A phase 1, open-label, randomized drug–drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies
B. Tariq, Y. Ou, J. Stern, Vaibhav Mundra +7 more
2022Leukemia and Lymphoma6 citations Open access
Semantic Scholar
Application of a Novel ‘Make and Test in Parallel’ Strategy to Investigate the Effect of Formulation on the Pharmacokinetics of GDC-0810 in Healthy Subjects
S. Cheeti, H. Hou, Eric Nelson, H. Walker +7 more
2018Pharmaceutical Research6 citations Open access
Semantic Scholar
The pharmacokinetics of pamiparib in the presence of a strong CYP3A inhibitor (itraconazole) and strong CYP3A inducer (rifampin) in patients with solid tumors: an open-label, parallel-group phase 1 study
S. Mu, Chester Lin, Anna Skrzypczyk-Ostaszewicz, I. Bulat +4 more
2021Cancer Chemotherapy and Pharmacology5 citations Open access
Semantic Scholar
Population pharmacokinetics of tislelizumab in patients with advanced tumors
C.-Y. Wu, T. Tang, L. Liu, Y. Ben +2 more
2019Annals of Oncology5 citations Open access
Semantic Scholar
A supported liquid extraction LC-MS/MS method for determination of concentrations of GDC-0425, a small molecule Checkpoint kinase 1 inhibitor, in human plasma.
Xiao Ding, Yuan Chen, S. Sahasranaman, Yi-Fan Shi +2 more
2016Biomedical chromotography5 citations
Semantic Scholar
Abstract CT139: Phase I study of GDC-0425, a checkpoint kinase 1 inhibitor, in combination with gemcitabine in patients with refractory solid tumors
J. Infante, A. Hollebecque, S. Postel-Vinay, T. Bauer +14 more
20155 citations
Semantic Scholar
Validation of a method for the determination of thiocyanate in human plasma by UV/VIS spectrophotometry and application to a Phase I clinical trial of GDC-0425
Y. Shin, H. Meijering, Fred H. van Heuveln, J. Wieling +3 more
20155 citations Open access
Semantic Scholar
Clinical Pharmacology Overview of Tislelizumab in Patients With Advanced Tumors With a Focus on Racial Impact
Tian Yu, Chi-Yuan Wu, S. Sahasranaman, Xianbin Tian +10 more
2025Clinical and Translational Science4 citations Open access
Semantic Scholar
Exposure-Response Relationship of the Bruton Tyrosine Kinase Inhibitor, Zanubrutinib (BGB-3111) in Patients with Hematologic Malignancies
Y. Ou, Kun Wang, Lucy Liu, Ashutosh Jindal +2 more
2019Blood4 citations
Semantic Scholar
The 30 mg Dose of Fexofenadine HCl 6 mg/mL Suspension is Bioequivalent to the Marketed 30 mg Tablet in Healthy Adult Subjects under Fasted Conditions: a Randomized, Crossover, Open-label Study
D. N. Morrison, S. Sahasranaman
20074 citations
Semantic Scholar
Determination of combined nitrogen in tungsten metal powder
S. P. Awasthi, S. Sahasranaman, M. Sundaresan
19674 citations
Semantic Scholar
Alternative Dosing Regimens of Tislelizumab Using a Pharmacometrics Model‐Based Approach
Ahsan Rizwan, Hugh Giovinazzo, Tian Yu, Yu-Ying Gao +10 more
2025Clinical and Translational Science3 citations Open access
Semantic Scholar
PB1926: EFFICACY AND SAFETY OF ONCE DAILY (QD) VS TWICE DAILY (BID) ZANUBRUTINIB FOR PATIENTS WITH VARIOUS B-CELL MALIGNANCIES: A COMPARATIVE SUMMARY OF CLINICAL DATA AND EXPOSURE-RESPONSE ANALYSES
C. Tam, M. Shadman, J. Sharman, G. Cull +11 more
2023HemaSphere3 citations Open access
Semantic Scholar
A Phase 1, Open‐Label, Fixed‐Sequence, Drug–Drug Interaction Study of Zanubrutinib with Rifabutin in Healthy Volunteers
B. Tariq, Stephanie Conto, A. Cohen, S. Sahasranaman +1 more
2023Clinical pharmacology in drug development3 citations Open access
Semantic Scholar
Correction to: Application of a Novel ‘Make and Test in Parallel’ Strategy to Investigate the Effect of Formulation on the Pharmacokinetics of GDC-0810 in Healthy Subjects
S. Cheeti, H. Hou, Eric Nelson, H. Walker +7 more
2018Pharmaceutical Research3 citations Open access
Semantic Scholar
Abstract 5421: Prediction of intratumoral TIGIT receptor occupancy after the treatment with anti-TIGIT antibodies
Dmitry Shchelokov, O. Demin, Ahsan Rizwan, Yun Zhang +3 more
2022Cancer Research2 citations
Semantic Scholar
Tislelizumab exposure-response analyses of efficacy and safety in patients with advanced tumors
C.-Y. Wu, N. Budha, Y. Gao, H. Castro +3 more
2019Annals of Oncology2 citations Open access
Semantic Scholar
A Quantitative Systems Pharmacology (QSP) Model to Predict Receptor Occupancy of Bruton's Tyrosine Kinase (BTK) Inhibitors in Peripheral Blood Mononuclear Cells, Bone Marrow and Lymph Nodes of Patients with B-Cell Malignancies
S. Sahasranaman, O. Demin, Dmitry Shchelokov, V. Musatova +2 more
2019Blood1 citations
Semantic Scholar
Alternative dosing regimens of tislelizumab proposed using modeling and simulation.
Ahsan Rizwan, Tian Yu, Yu-Ying Gao, Kun Wang +9 more
2025Journal of Clinical Oncology0 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

Y. Ou×13
Invite
Y. Ou — researcher profile on SciRah
Zhiyu Tang×9
Invite
Zhiyu Tang — researcher profile on SciRah
Yu-Ying Gao×8
Invite
Yu-Ying Gao — researcher profile on SciRah
W. Novotny×6
Invite
W. Novotny — researcher profile on SciRah

×5

Invite

N. Budha — researcher profile on SciRah

Li-Chuan Liu×5

Invite

Li-Chuan Liu — researcher profile on SciRah

Invite

Lucy Liu — researcher profile on SciRah

Invite

Ya Wan — researcher profile on SciRah

Invite

Yuan Chen — researcher profile on SciRah

Invite

Xiao Ding — researcher profile on SciRah

Invite

S. Mu — researcher profile on SciRah

Invite

M. Tawashi — researcher profile on SciRah